IL-5 Antibody (Hu212) [Unconjugated]

Direct ELISA binding curve demonstrating the recognition of Human Anti-Human IL‑5 (Research Grade Mepolizumab Biosimilar) Monoclonal Antibody (Catalog # MAB11433) to IL‑5. The target protein was coated onto the microplate well surface, followed by binding of the antibody. A goat anti-human HRP conjugate was used for detection.

Biosimilar antibody development at Bio-Techne includes in silico design and engineering to generate both light chain (lc) and heavy chain (hc) sequences for each antibody. After transfection of the dual expression vector, Bio-Techne’s biosimilar antibodies undergo rigorous application testing to ensure the final biosimilar product is suited for your research needs.

• Reactivity: Hu
• Applications: ELISA
• Clone: Hu212
• Clonality: Monoclonal
• Host: Human
• Conjugate: Unconjugated

IL-5 Antibody (Hu212) [Unconjugated] Summary

• Additional Information: Recombinant Monoclonal Antibody For Research Use Only.
• Immunogen: Human IL-5
• Specificity: Detects human IL-5 based on Mepolizumab therapeutic antibody.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Human
• Purity Statement: Protein A or G purified from cell culture supernatant

Applications/Dilutions

• Dilutions:
  • ELISA

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for IL-5 Antibody (Hu212) [Unconjugated]

• BCDF mu
• B-cell differentiation factor I
• BCGFII
• EDF
• Eo-CSF
• Eosinophil differentiation factor
• IL5
• IL-5
• IL-5T-cell replacing factor
• interleukin 5 (colony-stimulating factor, eosinophil)
• interleukin-5
• TRF
• TRFB cell differentiation factor I

Background

Mepolizumab is a humanized IgG1 k anti-IL5 monoclonal antibody. IL-5 is a key cytokine required for the maturation, activation, proliferation and survival of eosinophils making it an ideal target for therapeutic management of eosinophil levels in respiratory indications. Mechanistically, mepolizumab exerts its therapeutic function as an IL-5 antagonist to reduce eosinophil levels in the blood. IL-5 is 134-amino acid 52 kDa homodimeric protein with a four-helix domain. Mepolizumab specifically binds to the alpha -chain of IL-5, resulting in two IL-5 dimers being cross-linked by two molecules of mepolizumab. The highly specific binding of mepolizumab to IL-15 blocks ligation to IL-5Aa receptor. The biologic is primarily used for the management of moderate to severe asthma. Bio-Techne's Leronlimab biosimilar is produced using the full-length sequence which is identical to that of the original therapeutic antibody.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.